A quadrivalent nucleoside-modified messenger RNA influenza vaccine met superiority criteria compared with a licensed inactivated vaccine.

Gestational weight gain above or below the Institute of Medicine recommendations was associated with a greater risk for adverse outcomes.

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.

Patients with gout receiving oral ULT showed similar rates of MSU crystal dissolution in the joints and tendons.

Favorable physician job outcomes were associated with better nurse staffing adequacy, clinical care environments, and clinician teamwork.

Reductions in urinary arsenic were linked to significantly lower chronic disease mortality, cancer mortality, and CVD mortality.